Serious Adverse Events – Page 2 – Communicable Diseases Research

Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study

Clinical Trial

Published on 2022-09-012022-10-05
Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 진단,

Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults

Research article

Published on 2022-09-012022-10-05
Journal: Vaccine [Category] 임상, 진단, 치료기술,

[키워드] 95 % CI adverse event Adverse events of special interest analyses Analysis baseline Brighton Collaboration Coalition for Epidemic Preparedness Innovations collaboration Combined COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccine trials COVID-19 vaccines datasets evaluate exhibited higher risk Moderna Moderna COVID-19 vaccine mRNA-1273 mRNA mRNA COVID-19 vaccine mRNA vaccine mRNA vaccines NCT04368728 NCT04470427 outcomes Pfizer Pfizer-BioNTech COVID-19 vaccine BNT162b2 Placebo placebo-controlled randomized clinical trial randomized trial reported Result risk Safety Platform for Emergency vACcines SARS-CoV-2 secondary Serious Adverse Event Serious Adverse Events serious COVID-19 stratified the vaccine Trial Vaccines World Health Organization
[DOI] 10.1016/j.vaccine.2022.08.036 [Article Type] Research article

Efficacy of pharmacological interventions in COVID-19: A network meta-analysis

Covid-19의 약리학 적 개입의 효능 : 네트워크 메타 분석

Meta-Analysis

Published on 2022-09-012022-09-08
Journal: British Journal of Clinical Pharmacology [Category] meta-analysis, 임상, 치료제,

[키워드] 95% confidence interval Administered analysed Clinical improvement clinical recovery Controlled trial coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 database Dexamethasone drug Favipiravir followed by head Head-to-head comparison Hydroxychloroquine increase interferon Intervention investigator Lopinavir Lopinavir/ritonavir lower mortality lower risk lower risk of mortality MeSH term moderate to severe Mortality Network meta-analysis Occurrence patients with moderate pharmacological intervention Quantitative analysis Randomized controlled trial reduce reduced Relative risk Remdesivir risk Ritonavir screened Serious Adverse Event Serious Adverse Events severe COVID-19 significantly Standard of care Tocilizumab was performed
[DOI] 10.1111/bcp.15338 PMC 바로가기 [Article Type] Meta-Analysis

Compassionate Use of REGEN-COV® in Patients With Coronavirus Disease 2019 (COVID-19) and Immunodeficiency-Associated Antibody Disorders

코로나바이러스 2019(COVID-19) 및 면역결핍 관련 항체 장애 환자에서 REGEN-COV®의 자비로운 사용

Article

Published on 2022-08-242022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 신약개발, 진단,

[키워드] Adverse adverse events antibody Antibody deficiency B-cell B-cell deficiency Casirivimab Chain Reaction Clinical improvement clinical status compassionate use complications COVID-19 COVID-19 infection death Diagnosis disorder event higher risk Imdevimab immunodeficiency immunodeficient patient immunodeficient patients improvement infusion median time Medical conditions monoclonal antibody negative RT-PCR objective outcome oxygenation status Patient patients patients with COVID-19 polymerase chain reaction Quantitative REGEN-COV reported Retrospective analysis RT-PCR Serious Adverse Events subset Treatment viable treatment Viral viral clearance Viral load with COVID-19
[DOI] 10.1093/cid/ciab1059 PMC 바로가기 [Article Type] Article

Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273

Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV 및 mRNA-1273을 사용한 SARS CoV-2에 대한 이종 면역의 면역원성과 반응성

Article

Published on 2022-08-162022-09-11
Journal: Cell Reports Medicine [Category] SARS, 변종, 진단, 치료기술,

[키워드] Ad5-nCoV analyzed Anti-spike Antibody Response BBIBP-CorV ChAdOx1 ChAdOx1 vaccine ChAdOx1-S Cohort Combination coronavirus disease Coronavirus disease 2019 Coverage COVID-19 evaluate Heterologous heterologous vaccination heterologous vaccine highest homologous humoral Humoral response IgG immunization immunogenicity Immunoglobulin Immunoglobulin G information Messenger RNA mRNA mRNA-1273 nCoV Neutralizing antibodies observation observé omicron Omicron variant Participants platform provide reactogenicity Region SARS CoV-2 SARS-CoV-2 second dose Serious Adverse Event Serious Adverse Events Sputnik V Support titers vaccination Vaccine virus neutralizing titer virus neutralizing titers
[DOI] 10.1016/j.xcrm.2022.100706 PMC 바로가기 [Article Type] Article

Inactivated vaccine Covaxin/BBV152: A systematic review

비활성화 백신 Covaxin/BBV152: 체계적인 검토

Article

Published on 2022-08-092022-09-11
Journal: Frontiers in Immunology [Category] SARS, 변종,

[키워드] adjusted Administered adverse event Aluminium aluminium hydroxide Antigen AZD1222 BBV152 Beta Bharat binding antibody clinical trial Combination Corona Covaxin Coverage Covishield Delta Delta variants doses Effectiveness Efficacy Evidence evidence of fatality gel heterologous prime-boost hydroxide immunogenicity inactivated Inactivated vaccine India infected individual Local Neutralizing omicron Omicron variant pandemic phase Phase I Phase III trials provided Quinolin reported Safety safety profile SARS-CoV-2 pandemic screened searched second dose Serious Adverse Event Serious Adverse Events severe COVID-19 surpassed symptomatic infection systematic review systemic adverse events T cell T cell response T cell responses the SARS-CoV-2 Trial vaccination Vaccine Vaccines variant variants virus Zeneca
[DOI] 10.3389/fimmu.2022.863162 PMC 바로가기 [Article Type] Article

Mycophenolate mofetil decreases humoral responses to three doses of SARS-CoV-2 vaccine in liver transplant recipients

Mycophenolate mofetil은 간 이식 수혜자의 SARS-CoV-2 백신 3회 투여에 대한 체액 반응을 감소시킵니다.

Article

Published on 2022-08-012022-09-11
Journal: Liver international : official journal of the Inte [Category] COVID19(2023년), SARS, 진단, 치료기술,

[키워드] 95%CI Analysis anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody anti-SARS-CoV-2 vaccination antibody Antibody titre appear booster dose consultation decrease defined determine develop dose doses Efficacy enrolled Factor failure French Gender humoral Humoral response identify independent independent risk factor liver liver transplant male MMF mRNA mRNA vaccine mycophenolate mycophenolate mofetil Patient patients Predictive receiving recipient recipients responders response rate response to vaccination responsiveness risk factor Risk factors SARS-CoV-2 SARS-CoV-2 vaccine Serious Adverse Events Seroconversion Serologic response solid organ solid organ transplant the patient the vaccine Treatment vaccination Vaccine
[DOI] 10.1111/liv.15258 PMC 바로가기 [Article Type] Article

Genetic basis of sudden death after COVID-19 vaccination in Thailand

Research article

Published on 2022-08-012022-10-05
Journal: Heart Rhythm [Category] 변종, 유전자 메커니즘, 진단,

Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial

COVID-19 회복기 참가자에 대한 FINLAY-FR-1A 백신의 안전성 및 면역원성: 공개 라벨 2a상 및 이중 맹검, 무작위 배정, 위약 대조, 2b상, 심리스, 임상 시험

Clinical Trial

Published on 2022-08-012022-09-11
Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 변종, 임상,

[키워드] 95% CI adverse event All participants Alpha anti-RBD antibody assigned Asymptomatic Beta clinical clinical trial clinical trials Complete control group control groups convalescent convalescent individual convalescent individuals COVID-19 criteria Cuba defined delta variant Delta variants dimeric double-blind education elicited ELISA Endpoint enrolled Environment evaluate evaluated experimental group first stage geometric mean geometric mean titre geometric mean titres greater hematology ICTRP IgG antibodies immune response immunogenicity immunology increase in injected injection injection site Intervention intervention group Mild minor Moderate COVID-19 natural immunity Negative PCR neutralisation test neutralising antibody Occurrence Open-label Pain participant Participants PCR test per-protocol population Phase 1 Phase 2 Placebo placebo group placebo-controlled prevaccination Primary outcome Primary outcomes Public randomised Randomly Receptor binding domain recruited Registered registry reported Safety safety analysis safety population safety profile SARS-CoV-2 Science seamless secondary Secondary endpoints Serious Adverse Event Serious Adverse Events seroconversion rate sexual single dose stages study population technology the placebo group titre Trial two groups vaccination Vaccine vaccine immunogenicity Virus neutralisation Volunteer was done WHO-ICTRP
[DOI] 10.1016/S2213-2600(22)00100-X PMC 바로가기 [Article Type] Clinical Trial

Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study

일본 참가자의 S-268019-b 또는 BNT162b2 추가 용량의 면역원성과 안전성: 2/3상, 무작위, 관찰자 맹검, 비열등성 연구의 중간 보고서

Clinical Trial

Published on 2022-07-302022-09-11
Journal: Vaccine [Category] MERS, 변종, 임상, 진단,

[키워드] 95% CI analyzed Anti-spike antibodies BNT162b2 booster booster dose Booster vaccine clinical clinical trial co-primary endpoint co-primary endpoints COVID-19 Delta elicited fatigue Fever geometric mean geometric mean titer GMT GMT ratio immunization immunogenicity Immunoglobulin Immunoglobulin G injection Injection-site pain Interim report Interim result interim results Japanese Live virus MOST myalgia neutralization test Neutralizing antibodies neutralizing antibody observer observer-blinded omicron P-value participant phase 2/3 produced pseudovirus Randomized reactogenicity recombinant Recombinant spike protein regimen reported robust Safe SARS-CoV-2 SARS-COV-2 infection Serious Adverse Event Serious Adverse Events Spike protein subgroups T-cell Response Vaccine variant
[DOI] 10.1016/j.vaccine.2022.06.032 PMC 바로가기 [Article Type] Clinical Trial